



Bibliographic Review Presentation on *Adhesion Prevention in Tubal Surgery*

Dr.Tadesse Kitilla, Addis Ababa University, Ethiopia

Advisor:

**Dr.Chardonnens Didier, Consultant, Geneva
University, Switzerland.**

October 2000.

Rationale

- Ω **Clinical question in view of tubal infertility management IN MY ENVIRONMENT**
- Ω **Adhesion prevention - global perspective**
- Ω **Indicate possible solution to improve the condition**

Objectives

- ∞ **Acquire knowledge on pathogenesis of adhesion formation and re-formation to prevent it in clinical practice**
- ∞ **Participate or undertake clinical research trials that involve adhesion prevention activities in tubal surgery**

Review Methods

- ∩ Electronic data bases: MEDLINE, OVID
- ∩ Terms used: Adhesion prevention, tubal surgery, postoperative procedures
- ∩ Human and animal models
- ∩ English Publications from 1957 - 2000.
- ∩ 137 publications (16 reviews, 3 Cochrane)

Adhesion Pathogenesis

∞ **SURGICAL INJURY**



∞ **Stromal mast Cells disruption**



∞ **Release of vasoactive substances (histamines, kinines, leucotrienes)**



∞ **Increased blood vessel permeability**



∞ **Formation of fibrin exudates**

Pathogenesis continued...

Fibrin Exudate

∞ **Plasminogen..Plasmin**

∞ **Plasminogen activator**



∞ **Fibrinolysis**



∞ **Mesothelial
regeneration**



∞ **No Adhesion**

∞ **Plasminogen..Plasmin**

Decreased activator



∞ **Decreased
fibrinolysis**



∞ **Fibroblast
proliferation**



∞ **Adhesions**


Staging of tubal disease

Modified from Winston et al. 1991, Br. J. Ob. Gyn.

Stage I	<ul style="list-style-type: none">• Thin wall with good mucosa• Flimsy adhesions limited to the ampulla and ovary only• Ovary present and mainly free
Stage II	<ul style="list-style-type: none">• Thick wall with good mucosa• Thin wall with altered mucosa• Intraluminal adhesions• Fibrous thick adhesions involving tube and/or ovary
Stage III	<ul style="list-style-type: none">• Thick wall with altered mucosa• Clean hydrosalpinx with nodularity of patent isthmus• Ovary incarcerated against pelvic side wall or absent
Stage IV	<ul style="list-style-type: none">• Tubo ovarian mass or fibrous adherent hydrosalpinx with incarcerated ovary and or isthmic damage


Cumulative pregnancy rate after surgery for infective tubal damage

adapted from Wu et al. 1988




Laparoscopic salpingosotomies: fertility results according to tubal mucosa appearance

Adapted from Dubuisson et al. 1994



Postoperative adhesion prevention strategies



Classification of Adjuvant

∞ Nature

- **bio-degradable or not**
- **liquid or solid**

∞ Application time

- **preoperative**
- **intraoperative**
 - **before tissue injury**
 - **after tissue injury**
- **postoperative**
 - **hydrotubation**
 - **2nd look laparoscopy**

∞ Administration route

- **intraperitoneal**
- **oral**
- **parenteral**

∞ Mechanism of action

- **mechanical (barrier)**
- **anti-inflammatory**
- **Fibrin inhibitors**
- **fibrinolytics**
- **protect tissue damage**

Mechanisms of action

∞ Anti-inflammatory

- corticosteroids, other steroids, NSAID, Promethazine, calcium channel blockers, pentoxifylline.

∞ Fibrin inhibitors

- heparin, sodium citrate, Ringer`s lactate

∞ Promote fibrinolysis

- tissue enzymes

∞ Mechanical barriers

- solid
 - PTE, (Gare-Tex) TC7,
- liquid or gelatinous
 - Seprafilm, Sepracoate, fibrin glue, surgicel, polyethylene glycol hydrogel, 32% dextran 70, Ringer lactate etc.

∞ Prevention of tissue damage

- hydrophilic polymer solutions



Review Summary - Surgery

Ω Surgical techniques (microsurgery vs laparoscopy) and modalities

Review Summary - Adjuvant

∞ **No ideal adjuvant**

∞ **Among the available in priorities**

- **PTFE (Gore-Tex, Preclude)**
- **Interceed (TC-7)**
- **Seprafilm, Genzyme**
- **Polyethylene glycol hydrogel**
- **Hyaluronic acid**
- **Chondroitin Sulphate**
- **Fibrin sealants (glue)**

Conclusion

- ⌚ *Is the clinical question answered?*
- ⌚ **Knowledge and practical skills.**
- ⌚ **How about conventional and adjuvant?**
- ⌚ **Can barriers be specific for tubo-ovarian surface?**